Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients

Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients

Abstract Paroxysmal nocturnal hemoglobinuria (PNH) results from a mutation in the phosphatidylinositol glycan class-A gene which causes uncontrolled complement activation with resultant intravascular hemolysis and its sequelae. Eculizumab is a terminal complement inhibitor that blocks this complemen...

Full description

Bibliographic Details
Main Authors: Sugat Adhikari, Surendra Sapkota, Suraj Shrestha, Kshitiz Karki, Anjan Shrestha
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Catastrophic health expenditure
Eculizumab
Low and middle-income countries
Orphan drug
Paroxysmal nocturnal hemoglobinuria
Nepal
Online Access:https://doi.org/10.1186/s13023-023-02779-2

Internet

https://doi.org/10.1186/s13023-023-02779-2

Similar Items